Remodelling of extracellular matrix in rectal cancer and preoperative radiotherapy by Angenete, Eva
 ISBN: 978-91-628-7733-0   Göteborg 2009 
REMODELLING OF EXTRACELLULAR MATRIX IN RECTAL CANCER 
AND PREOPERATIVE RADIOTHERAPY 
AKADEMISK AVHANDLING 
 
Som för avläggande av medicine doktorsexamen vid Sahlgrenska Akademin vid Göteborgs 
Universitet kommer att offentligen försvaras i Humlen, Servicehuset, Sahlgrenska 
Universitetssjukhuset/Östra Sjukhuset, Göteborg 
fredagen den 24 april 2009 kl. 13.00 
 
av 
 
Eva Angenete 
 
Fakultetsopponent: 
Docent Per-Anders Larsson 
Kirurgkliniken 
Helsingborgs lasarett 
 
Avhandlingen baseras på följande delarbeten: 
 
I. Matrix metalloproteinases in rectal mucosa, tumour and plasma: response after 
preoperative irradiation. 
Angenete E, Langenskiold M, Falk P, Ivarsson ML, 
Int J Colorectal Dis 2007;22(6):667-74 
 
II. Transforming growth factor beta-1 in rectal tumour, mucosa and plasma in relation to 
radiotherapy and clinical outcome in rectal cancer patients. 
Angenete E, Langenskiold M, Palmgren I, Falk P, Oresland T, Ivarsson ML, 
Int J Colorectal Dis 2007;22(11):1331-8 
 
III. uPA and PAI-1 in Rectal Cancer-Relationship to Radiotherapy and Clinical Outcome. 
Angenete E, Langenskiold M, Palmgren I, Falk P, Oresland T, Ivarsson ML, 
J Surg Res 2008 Apr 7 (Epub ahead of print) 
 
IV. Preoperative radiotherapy and extracellular matrix remodelling in rectal mucosa and 
tumour. Matrix metalloproteinases and plasminogen components 
Angenete E, Öresland T, Falk P, Breimer M, Hultborn R, Ivarsson ML, 
Submitted for publication 
 
 
 
 ISBN: 978-91-628-7733-0   Göteborg 2009 
ABSTRACT 
BACKGROUND 
Preoperative radiotherapy reduces local recurrence due to rectal cancer, but increases 
postoperative morbidity. The aim of this thesis was to study the impact of radiotherapy on 
extracellular matrix (ECM) remodelling enzymes and growth factors after radiotherapy and also 
their possible use as surrogate markers for complications. A secondary aim was to explore the 
use of these enzymes and growth factors as markers for tumour classification and risk 
predictors of metastases and death of rectal cancer. 
 
MATERIALS AND METHODS 
In paper I-III 91-110 patients undergoing surgery with or without preoperative radiotherapy 
were studied through biopsies taken from tumour tissue and adjacent mucosa as well as plasma 
samples during surgery. Clinical parameters were registered and the patients were followed 
yearly. Paper IV encompasses 32 patients with sequential biopsies before treatment and from 
the surgical specimen. Twenty of them received preoperative radiotherapy. Protein levels of 
matrix metalloproteinase (MMP)-1, -2, -9 (Papers I and IV), urokinase plasminogen activator 
(uPA) (Papers III-IV), plasminogen activator inhibitor-1 (PAI-1) (Papers III-IV), transforming 
growth factor-β1 (TGF-β1) (Papers II and IV), tissue inhibitor of matrix metalloproteinases-1 
(TIMP-1) (Paper IV) and calprotectin (Paper IV) were determined by ELISA. Biopsies from 
irradiated and non-irradiated peritoneal areas were also analysed (Paper IV) for tissue-type 
plasminogen activator (tPA). The localisation of calprotectin in mucosa was determined by 
immunohistochemistry (Paper IV). 
 
RESULTS 
MMP-2 and PAI-1 levels were higher after radiotherapy in both mucosa and tumour whereas 
uPA and calprotectin were higher in mucosa after radiotherapy. High levels of MMP-2 
correlated to wound-infections and fistula formation. Peritoneal biopsies displayed lower levels 
of tPA in irradiated patients indicating a reduced fibrinolytic capacity. Levels of MMP-1, -2, -9, 
uPA, PAI-1, total TGF-β1 and calprotectin were higher in tumour tissue compared to mucosa. 
High levels of total TGF-β1 in tumour tissue correlated to the presence of metastases and high 
levels of PAI-1 in tumour tissue were associated with lateral spread irrespective of radiotherapy. 
PAI-1 in tumour tissue was also associated with an increased risk of death due to rectal cancer 
in multivariate analysis. 
 
CONCLUSIONS 
The ECM remodelling proteases and growth factors mirror to some extent the response to 
radiotherapy and may be involved in the pathogenesis of radiotherapy associated morbidity. 
MMP-2 can be related to clinically evident complications after surgery and radiotherapy and 
could be explored further for use as a clinical marker. To further improve selection of patients 
for radiotherapy the levels of TGF-β1 and PAI-1 in tumour tissue could be of use in 
preoperative assessment. 
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